Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIPR001 in Hematologic Malignancy Patients Undergoing Allo-HSCT with FQR E. Coli
NCT06938867Phase 2Recruiting
- Sponsor
- SNIPR Biome
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- CRISPR-Cas9, Gene Silencing, Single Strain Products
- Countries
- 1
01
Overview
A Phase 2 trial of SNIPR001 in Escherichia coli infection, sponsored by SNIPR Biome. Started Dec 2024; status: recruiting.
02
Drugs
SNIPR001
03
Conditions
Escherichia coli infection
Beyond the preview
Go deeper on NCT06938867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938867.